TO THE EDITOR
Adult T-cell leukemia (ATL), a leukemia/lymphoma of mature CD4 þ T cells associated with HTLV-I infection, is characterized by constitutive expression of CD25 (IL-2 receptor a chain) on leukemic cells and marked immunodeficient state of the patients.
1 While a decrease in naïve T cells has been described in ATL that partly accounts for the immunodeficient state, there may be other underlying mechanisms that suppress the overall immune response. Indeed, it was reported more than 25 years ago that ATL cells had suppressive activity on pokeweed mitogen-stimulated immunoglobulin production.
2 However, this property has not been thoroughly investigated because of the ambiguity of the definition of suppressor T cells at that time.
On the other hand, recent evidence has indicated that there is a distinct population of CD4 þ CD25 þ regulatory T cells (Treg) in mice as well as in humans that are engaged in the maintenance of immunologic self-tolerance.
3 Foxp3, a transcription factor, that is genetically defective in an autoimmune and inflammatory syndrome in both humans and mice, is specifically expressed in Treg and now considered to be a master regulatory gene for cell-lineage commitment or developmental differentiation of Treg.
Now that the presence of Treg with the distinct phenotype similar to ATL cells is substantiated, we addressed the long pending question on ATL and immune regulation by first measuring the expression of Foxp3 in 20 ATL cases and three CD4 þ T-cell-type chronic lymphocytic leukemia (T-CLL) cases in comparison with normal CD4 þ as well as CD4 þ CD25 þ T cells. All the samples were obtained with the informed consent of the patients and the approval of the doctors of the participating hospitals. The relative expression of Foxp3 mRNA was estimated by the ratio of the Foxp3 value to the HPRT value. As shown in Figure 1 , not all but some ATL cases and one T-CLL case showed significant expression of Foxp3 and the expression levels of Foxp3 were very heterogeneous among the cases. In all, 10 out of 20 ATL cases and one out of three T-CLL cases showed higher levels of Foxp3 than CD4 þ T cells and in five ATL cases the amount of Foxp3 was comparable to CD4 þ CD25 þ T cells, while there were cases that expressed very low levels of Foxp3. We tentatively defined Foxp3 high as higher than CD4 þ T cells and Foxp3 low as lower than or comparable to PBMC.
Normal Treg have been reported to express CTLA-4 and GITR without particular stimulation.
4,5 So we next examined whether either of these molecules was expressed on ATL cells. As shown in Figure 2a , ATL cells of a representative Foxp3 high case and normal CD4 þ CD25 þ T cells expressed considerable levels of CTLA-4 whereas normal unfractionated CD4 þ T cells and ATL cells of a representative Foxp3 low case expressed very low levels of CTLA-4. We examined CTLA-4 expression in 10 ATL cases (four Foxp3 high cases and six Foxp3 low cases) and found that there was a significant correlation between Foxp3 expression and %CTLA-4 þ cells with a correlation coefficient of 0.006 ( Figure 2b ). As to GITR, only a small population of each sample expressed low levels of GITR (data not shown).
It is known that leukemic cells of the majority of ATL patients secrete TGF-b but not IL-2 or IFN-g and hardly respond to exogenous IL-2. 6 In accordance with the previous reports, none of ATL cells of the representative four cases (two Foxp3 high and two Foxp3 low) produced IL-2 or IFN-g upon stimulation with ionomycin and PMA, while one Foxp3 high case showed significant production of TGF-b (data not shown). Production of TGF-b is notable because recent evidence has indicated that CD4 þ CD25 À conventional T cells can differentiate into Treg with high expression of Foxp3 when stimulated and cultured in the presence of TGF-b.
7 Moreover, human Treg and Tregderived T-cell clones have been reported to produce TGF-b that presumably plays a role in their immunoregulatory function. Thus, TGF-b may be involved in immune regulation in ATL as discussed below.
We examined the suppressive activity of ATL cells on proliferation of normal CD4 þ T cells stimulated with autologous DC and anti-CD3 mAb. In this assay, the cell division cycle was visualized as the phased decrease in immunofluorescence intensity of CFSE. Although we could not verify the significant difference due to the limited availability of the samples, there was a tendency that the ratio of cells that underwent more than two cell divisions decreased in coculture with Foxp3 high ATL cells compared to that with normal CD4 þ T cells or Foxp3 low ATL cells (data not shown).
These results suggest that Foxp3 high ATL cells resemble Treg phenotypically as well as functionally. Hence, there are two possibilities as to the origin of these ATL cells as follows. One is that they derived from naturally occurring CD4 þ CD25 þ Treg and, after HTLV-I infection, underwent malignant transformation. These leukemic cells preserved phenotypic as well as functional features of Treg. In mice, evidence has indicated that a subset of Treg is steadily activated and proliferating, which obviously renders them more susceptible to malignant transformation than other resting T cells.
8 Consistent with this is that the frequency of ATL cases with significant Foxp3 expression was higher than that of Treg in normal CD4 þ T cells. Thus, according to this scenario, we can speculate that leukemic cells of most ATL cases were derived from Treg but, after transformation, expression of Foxp3 were downregulated in some cases for unknown reason. The other possibility is that ATL cells derived from CD4 þ CD25 À conventional T cells and, after malignant transformation, they acquired the phenotype of CD4 þ CD25 þ together with the induction of Foxp3 expression. In this assumption, the malignant transformation does not always cause upregulation of Foxp3 because there were cases that did not express Foxp3. Rather, autocrine or paracrine TGF-b may play a role in differentiation of ATL cells into Treg-like cells. At present it is difficult to determine which of these possibilities is more likely and we think they are not mutually exclusive during the development of ATL.
Regardless of their origin, Foxp3 high ATL cells are likely to suppress immune response also in vivo with constitutive expression of CTLA-4 and in some cases with TGF-b. Such function may be involved not only in escape of leukemic cells from immunologic surveillance of the host but also in generation of the immunodeficient state of ATL. Further studies are required to define the pathophysiological relevance of our findings and to delineate clinical features of Foxp3 high ATL cases in comparison with Foxp3 low cases.
